<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03395470</url>
  </required_header>
  <id_info>
    <org_study_id>PXL770-002</org_study_id>
    <nct_id>NCT03395470</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PK of PXL770 in Healthy Male Subjects</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of PXL770, Including an Open-label, One-sequence Part to Assess the Drug-drug Interaction With Rosuvastatin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poxel SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poxel SA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK)
      being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM). In Part A
      of this study, we'll test the safety, tolerability and pharmacokinetics (PK) of repeated
      doses. In Part B, we'll co-administer PXL770 and rosuvastatin (a HMG-CoA reductase inhibitor)
      to assess any drug-drug interaction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Anticipated">May 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: PK parameters of PXL770 after repeated doses Part B: PK parameters of rosuvastatin before and after repeated doses of PXl770</measure>
    <time_frame>From baseline to day 14</time_frame>
    <description>- Cmax: peak plasma concentration after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: PK parameters of PXL770 after repeated doses</measure>
    <time_frame>From baseline to day 14</time_frame>
    <description>- AUC0-t: area under the concentration-time curve from 0 extrapolated to time t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: PK parameters of PXL770 after repeated doses</measure>
    <time_frame>From baseline to day 14</time_frame>
    <description>- AUC0-∞: area under the concentration-time curve from 0 extrapolated to infinite</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>From baseline to day 14</time_frame>
    <description>Incidence of treatment emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Metabolic Disease</condition>
  <arm_group>
    <arm_group_label>Group A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 5 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose + Rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXL770</intervention_name>
    <description>MAD</description>
    <arm_group_label>Group A1</arm_group_label>
    <arm_group_label>Group A2</arm_group_label>
    <arm_group_label>Group A3</arm_group_label>
    <arm_group_label>Group A4</arm_group_label>
    <arm_group_label>Group A5</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>MAD</description>
    <arm_group_label>Group A1</arm_group_label>
    <arm_group_label>Group A2</arm_group_label>
    <arm_group_label>Group A3</arm_group_label>
    <arm_group_label>Group A4</arm_group_label>
    <arm_group_label>Group A5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>DDI</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects deemed healthy on the basis of a clinical history, physical examination,
             ECG, vital signs, and laboratory tests of blood and urine

          -  body mass index in the range 18.5-29.9 kg/m²

          -  body weight at least 60 kg

          -  willing to use reliable contraception

          -  able to give fully informed written consent.

        Exclusion Criteria:

          -  Pregnant or lactating woman, or sexually active woman of child-bearing potential not
             using reliable contraception

          -  Clinically relevant abnormal findings at the screening assessment

          -  Clinically significant vital signs outside the acceptable range at screening

          -  Clinically relevant abnormal medical history, surgery or concurrent medical condition

          -  Acute or chronic illness

          -  Estimated glomerular filtration rate less than 80 mL/min/1.73 m2

          -  Severe adverse reaction to any drug or sensitivity to the trial medication or its
             components

          -  Significant food allergy; vegetarian or vegan

          -  Participation in other clinical trials of unlicensed or prescription medicines, or
             loss of more than 400 mL blood, within the 3 months before first dose of trial
             medication

          -  Drug or alcohol abuse

          -  Smoking of more than 5 cigarettes daily

          -  Possibility that subject will not cooperate

          -  Positive test for hepatitis B &amp; C, HIV

          -  Objection by a General Practitioner
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research (HMR)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denisa Wilkes, MBBS</last_name>
      <phone>+44 (0)20 8961 4130</phone>
      <email>dwilkes@hmrlondon.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

